China
Africa
Explore chapters and articles related to this topic
Vesiculobullous Diseases
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Snejina Vassileva, Kossara Drenovska
Management: Treatment has to take into account the patient’s general condition, disease severity, and comorbidities. High-potency topical steroids (clobetasol propionate cream) and systemic steroids (0.5–0.75 mg/kg/day) are recommended in both extensive and localized/limited or mild BP. The use of a steroid-sparing adjuvant, such as doxycycline (200 mg/day) and dapsone (1.5 mg/kg/day), and immunosuppressants, including azathioprine (1–3 mg/kg/day), cyclosporine (3–5 mg/kg/day), mycophenolate mofetil (2 g/day), and methotrexate (15 mg/week), are reserved to cases unresponsive to corticosteroids. Alternatively, IVIG, rituximab, omalizumab, immunoadsorbtion, and plasma exchange may be considered in severe or recalcitrant cases.
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Three similar case reports had been published previously (6,7,8). The patients all noted an exacerbation of eczema while using clobetasone butyrate cream and/or ointment. Patch tests were positive to the topicals and to clobetasone butyrate, tested in various concentrations. All three patients also reacted to clobetasol propionate. These were more likely co-sensitizations than cross-reactions, as the patients all had used pharmaceuticals with this corticosteroid also (6,7,8).
Topical Therapies for Psoriasis
Published in Siba P. Raychaudhuri, Smriti K. Raychaudhuri, Debasis Bagchi, Psoriasis and Psoriatic Arthritis, 2017
Treatment of genital and intertriginous psoriasis should first correct harmful habits like the excessive use of detergents and inappropriate cosmetic products. Fragrance-free liquid soaps should be used atraumatically, followed by careful drying. Loosely fitting underwear should be frequently changed. Whereas the vulva is relatively steroid resistant, labiocrural folds, the perineum, and perianal regions are steroid sensitive [106–108]. At these sites, care should be taken to avoid extended use of topical corticosteroids of higher strength. Whereas hydrocortisone is mostly uneffective, methylprednisolone aceponate and mometason are recommended. Clobetasol propionate will only be necessary in severe and recalcitrant cases. Similar to other sites, corticosteroids should be started at higher strength and de-escalated stepwise as quickly as possible. Proactive therapy should be continued after disappearance of skin manifestations with application 2 days weekly at originally affected sites. Alternatively, topical calcineurin inhibitors like tacrolimus and pimecrolimus can be used [92–98].
Side effect jiu-jitsu
Published in Journal of Dermatological Treatment, 2022
Rithi Chandy, Katherine L. Keith, Steven R. Feldman
Side effect jiu-jitsu may also be used in the treatment of scalp psoriasis and related dermatoses. Clobetasol propionate is a commonly prescribed treatment for scalp psoriasis. Burning or stinging at the application site is a common adverse effect. If patients experience burning unexpectedly, they may discontinue treatment immediately. Even if they are warned that burning may occur, they may feel the need to stop the treatment. However, if told that burning or tingling is a sign that the medication is “working”, patients may be more inclined to use the treatment (10). The burning/stinging sensation does indicate the medication is working, as the burning/stinging is evidence that the medication was successfully applied to the scalp, and not just to the hair. Dermatologists can use this patient belief system to encourage continued use by reassuring patients that the sensation is both expected and normal, and indicates the medication is indeed “doing its job”.
Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis
Published in Journal of Microencapsulation, 2020
Ankita Dadwal, Neeraj Mishra, Ravindra K. Rawal, Raj Kumar Narang
Clobetasol propionate is a very potent topical corticosteroid class compound. Topical steroids are used in addition to moisturisers for treating inflammatory skin conditions such as eczema and dermatitis. Owing to its anti-inflammatory, antipruritic and immune-modulating properties, clobetasol propionate is used to treat psoriasis (Decroix et al.2004). Clobetasol propionate induces phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2 (Schäfer-Korting et al.2005). It was also found that if clobetasol propionate (CP) was incorporated in the nanoemulsion it shows significant increase in their anti-inflammatory activity. It was reported that CP-loaded nanoemulsion significantly increased NTPDase (Nucleoside triphosphate diphosphohydrolases) activity in lymphocytes. This membrane protein is responsible for the hydrolysis of extracellular ATP (Adenosine triphosphate) which is responsible for cell proliferation, differentiation and inflammatory processes (Alam et al.2013).
Complications and posttreatment care following invasive laser skin resurfacing: A review
Published in Journal of Cosmetic and Laser Therapy, 2018
Dan Li, Shi-Bin Lin, Biao Cheng
The rates of postinflammatory hyperpigmentation differed among skin phototypes III, IV, and V (2.6, 11.6, and 33%, respectively) in an investigation of fractional LSR(37). Obviously, the risk of hyperpigmentation for individuals with a dark complexion may only be controlled to some extent. Wanitphakdeedecha demonstrated that the use of broad-spectrum sunscreen on the first day after fractional LSR may decrease the incidence of PIH during the first week(78). However, in a study by Boonchai, the author found that the early application of sunscreen from day 1 might increase the risk of sensitization because the skin barrier was not fully healed. Thus, he recommended that sunscreen be used from day 3(79). Cheyasak undertook a split-face comparison study of patients after LSR. One side was randomly selected for treatment with clobetasol propionate 0.05% ointment for the first 2 days and then changed to petrolatum for the subsequent 5 days, while petrolatum alone was used on the control side. The results showed that despite the short-term use, the topical corticosteroid reduced the incidence of PIH (40%) more than the petrolatum-only treatment (75%)(80).